Study confirms the causal effect of PECAM-1 on cardiovascular diseases

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Platelet endothelial cell adhesion molecule (PECAM-1) is present in the vascular endothelium and plays important roles in various biological processes. Several recent studies have reported associations between PECAM-1 and certain subtypes of cardiovascular diseases (CVDs). However, further research is necessary to clarify the causal effects of PECAM-1 on CVDs.

To determine whether PECAM-1 and CVDs are causally associated, the authors of this article conducted a two-sample Mendelian randomization (TSMR) study.

Single nucleotide polymorphisms (SNPs) associated with PECAM-1 were used as instrumental variants (IVs) to estimate the causal effects of PECAM-1 on CVDs. Six SNPs were included in the TSMR study. The inverse-variance weighted (IVW) method was applied in the primary analysis. To confirm the initial results, several complementary analyses and pleiotropy analyses were conducted.

In the IVW analysis, higher genetically predicted PECAM-1 levels were associated with lower risk of coronary artery disease (CAD) (OR, 0.835; CI, 0.757-0.92; P = 3 × 10−4) and myocardial infarction (MI) (OR, 0.79; CI, 0.709-0.881; P = 2.03 × 10−5).

The findings confirmed that elevated PECAM-1 levels may decrease the risk of CAD and MI. These results confirm the causal effect of PECAM-1 on CVDs and may facilitate further investigation of the mechanism of PECAM-1 in CVD pathogenesis.

Source:
Journal reference:

Sun, M., et al. (2024). Causal Relationship between PECAM-1 Level and Cardiovascular Diseases: A Mendelian Randomization Study. Cardiovascular Innovations and Applications. doi.org/10.15212/cvia.2024.0032.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cell therapy offers effective treatment for patients with T-cell acute lymphoblastic leukemia